Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VESTA: Fezolinetant in Menopausal VMS
NCT03192176Phase 2Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of fezolinetant in vasomotor symptoms, sponsored by Astellas Pharma. Primary endpoints: Change From Baseline in The Mean Frequency of Moderate to Severe Vasomotor Symptoms at 12 weeks and Change From Baseline in The Mean Severity of Moderate to Severe Vasomotor Symptoms at 12 weeks. Started Jul 2017; status: completed.
02
Drugs
fezolinetant
03
Conditions
vasomotor symptoms
Beyond the preview
Go deeper on NCT03192176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03192176.